OakChart

IGC Pharma Inc

IGCHealthcare·Biotechnology·USA·Nano·AMEX·Nov 11 • 3:43 PM ET

0.1919-0.0041 (-2.09%)
2026-11-11 21:47 CET
Market cap
22.87 USD m
Revenue, TTM
1.26 USD m
Net income, TTM
-8.11 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.08
P/E
-
Compare

Price

IGC against its 20, 50 and 200-day averages
2050200earnings
0.100.200.302.0M4.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IGCclose 0.1920-day 0.2250-day 0.26200-day 0.280.1952w low

52.5% under the 52-week high of 0.40 on 11 Nov 2025. 52-week low 0.08 on 29 Oct 2026. Last 15 sessions, 221.3% high to low

Volume 0.22× normal · the line is the 50-bar volume average

Profile

IGC
52-week range, 35% of the way up
0.080.40

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Employees70
IPOApr 13, 2006
Beta0.54
ATR, 14d0.02
Rel volume0.22
Short float0.46%
Insider own25.88%
Inst own4.70%

Snapshot

6 groups

Valuation

Index-
Market Cap22.39M
Enterprise Value22.85M
Income-8.11M
Sales1.26M
Book/sh0.06
Cash/sh0.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees70
IPOApr 13, 2006

Ratios

P/E-
Forward P/E-
PEG-
P/S17.77
P/B3.38
P/C54.61
P/FCF-
EV/EBITDA-
EV/Sales18.14
Quick Ratio0.21
Current Ratio0.42
Debt/Eq0.13
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.08
EPS next Y-0.08
EPS next Q-0.02
EPS this Y-100.00%
EPS next Y20.00%
EPS next 5Y-
EPS past 3/5Y40.07% 25.84%
Sales past 3/5Y8.35% 5.23%
EPS Y/Y TTM-2.96%
Sales Y/Y TTM-6.51%
EPS Q/Q6.97%
Sales Q/Q71.73%
EarningsNov 09 BMO
EPS/Sales Surpr.0.00% 241.67%

Ownership

Insider Own25.88%
Insider Trans0.00%
Inst Own4.70%
Inst Trans1.09%
ROA-83.30%
ROE-111.15%
ROIC-122.34%
Gross Margin2.70%
Oper. Margin-802.70%
Profit Margin-643.65%
SMA20-12.76%
SMA50-24.76%
SMA200-30.37%
Trades-

Technical

Shs Outstand114.35M
Shs Float86.49M
Short Float0.46%
Short Ratio0.52
Short Interest0.40M
52W High0.40 -52.51%
52W Low0.08 139.88%
Volatility8.53% 16.13%
ATR (14)0.02
RSI (14)32.94
Beta0.54
Rel Volume0.22
Avg Volume755.84K
Volume157,585

Performance

Perf Week-1.59%
Perf Month-27.58%
Perf Quarter-34.73%
Perf Half Y-35.17%
Perf YTD-31.81%
Perf Year-50.37%
Perf 3Y-34.95%
Perf 5Y-86.58%
Perf 10Y-47.38%
Recom1.00
Target Price6.00
Prev Close0.20
Price0.19
Change %-2.09%

Peers

Mkt cap
TickerCompanyMkt cap
ALZNAlzamend Neuro Inc6.22M
ANVSAnnovis Bio Inc36.02M
AVXLAnavex Life Sciences Corp98.72M
CGTXCognition Therapeutics Inc64.35M
BIVIBioVie Inc13.41M
ACOGAlpha Cognition Inc188.60M
ARTLArtelo Biosciences Inc1.20M
LEXXLexaria Bioscience Corp9.99M
PMNProMIS Neurosciences Inc33.63M
ABOSAcumen Pharmaceuticals Inc16.96M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
PRINS RICHARD KDirectorApr 01 '26Option Exercise0.00170,00001,541,251Apr 06 04:02 PM
Mukunda RamCEOApr 01 '26Option Exercise0.13656,41084,0004,649,088Apr 06 04:02 PM
Mukunda RamCEOApr 01 '26Option Exercise0.0049,9990910,751Apr 06 04:02 PM
Moran James PDirectorApr 01 '26Option Exercise0.00130,00001,235,735Apr 06 04:02 PM
GRIMALDI CLAUDIAPFOApr 01 '26Option Exercise0.15238,46236,0001,372,714Apr 06 04:01 PM
Mukunda RamCEOFeb 03 '26Option Exercise0.0050,0000860,752Feb 04 05:31 PM
PRINS RICHARD KDirectorJan 19 '26Option Exercise0.00100,00001,371,251Jan 20 04:01 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
PSILAdvisorShares Psychedelics ETFAUM: 43.26M

News

latest 14 of 200
  • IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update (ACCESSWIRE)
  • IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears (ACCESSWIRE)
  • IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment (ACCESSWIRE)
  • IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 (ACCESSWIRE)
  • IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure (ACCESSWIRE) -5.98%
  • IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout (ACCESSWIRE) +5.05%
  • IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow (ACCESSWIRE)
  • IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company (ACCESSWIRE)
  • IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow (ACCESSWIRE)
  • IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis (ACCESSWIRE)
  • Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts (ACCESSWIRE)
  • IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis (ACCESSWIRE)
  • IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment (ACCESSWIRE)
  • IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.064-0.116-0.185-0.21-0.3-0.219-0.221-0.093-0.047-0.0801
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.024-0.016-0.019-0.02-0.008-0.025-0.029-0.019
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual2.1935.1164.0720.8980.3970.9111.3451.2711.1591.26
Period201720182019202020212022202320242025TTM
Sales, quarterly0.2570.290.3280.1910.350.3170.2650.328
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual30.76439.50139.3247.82751.05453.07766.69180.87895.038114.35
Period201720182019202020212022202320242025MRQ
Shares, quarterly78.20380.87884.14191.95995.03898.796102.417114.35
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.261.161.271.340.910.400.904.075.12
Cost of Goods Sold Incl. D&A1.231.141.221.181.070.831.254.094.98
Gross Profit0.030.020.050.17-0.16-0.43-0.35-0.020.13
Selling, General and Administrative Excl. Other10.1510.357.509.9711.4114.998.386.844.78
Research and Development5.165.233.653.773.462.330.931.011.26
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-10.11-10.33-7.45-9.80-11.57-15.43-8.72-6.86-4.64
Unusual Expense0.000.000.003.350.00-0.380.170.78-0.30
Net Income Before Taxes-8.11-5.53-7.12-13.00-11.51-15.02-8.81-7.32-4.09
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-8.11-5.53-7.12-13.00-11.51-15.02-8.81-7.32-4.10
Net Income From Continuing Operations-8.11-5.53-7.12-13.00-11.51-15.02-8.81-7.32-4.10
Net Income-8.11-5.53-7.12-13.00-11.51-15.02-8.81-7.32-4.10
EPS (Recurring)-0.07-0.06-0.09-0.18-0.22-0.31-0.21-0.17-0.12
EPS (Basic, Before Extraordinaries)-0.08-0.05-0.09-0.22-0.22-0.30-0.21-0.19-0.12
EPS (Diluted)-0.08-0.05-0.09-0.22-0.22-0.30-0.21-0.19-0.12
EBITDA-9.88-9.89-6.83-9.16-10.91-14.78-8.25-6.72-4.58
Non-Operating Income (Expense)2.004.800.330.140.070.030.080.330.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.422.951.641.775.507.000.700.380.38
Price To Sales Ratio23.3721.5817.1617.5019.59119.4983.654.7514.39
Gross Margin2.701.734.0912.64-17.34-109.07-38.86-0.472.58
Operating Margin-802.70-891.25-585.84-728.48-1,270.14-3,886.15-971.49-168.57-90.75
Net Margin-643.65-477.10-560.27-966.54-1,263.01-3,782.37-981.18-179.64-80.08
Shares Outstanding114.3595.0480.8866.6953.0851.0547.8339.3239.50
Market Capitalization22.8722.8722.7125.4918.0248.4581.2119.2782.34

Income statement, quarterly

No statement data.

Balance sheet, annual

No statement data.

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--4.15-7.12-13.00-11.51-15.02-8.81-7.32-4.10
Depreciation-0.320.620.640.660.650.480.140.06
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)--1.131.785.273.014.370.831.550.33
Funds from Operations--4.95-4.72-7.09-7.84-10.00-7.51-5.62-3.71
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.23-0.071.890.792.54-3.29-3.060.38
Cash from Operating Activities--4.72-4.79-5.20-7.05-7.46-10.80-8.68-3.33
Capital Expenditures--0.65-0.48-0.52-0.62-0.74-1.59-4.47-0.06
Net Assets From Acquisitions-0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.680.040.040.540.000.050.00-
Purchase or Sale of Investments--0.050.000.15-0.150.004.930.000.00
Purchase of Investments--0.050.000.00-0.150.00-0.150.000.00
Sale Or Maturity of Investments-0.000.000.150.000.005.080.000.00
Other Uses-0.000.000.000.000.000.00-5.08-0.20
Other Sources-0.000.000.000.000.000.00--
Cash from Investing Activities--0.02-0.44-0.32-0.23-0.743.39-9.55-0.26
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Change in Capital Stock-5.234.453.530.104.1414.160.0629.48
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-5.234.453.530.104.1414.160.0629.48
Proceedsfrom Stock Options-5.234.453.530.104.1414.160.0629.46
Issuance or Reduction of Debt, Net--0.00-0.00-0.00-0.00-0.000.530.00-1.88
Change in Long Term Debt--0.00-0.00-0.00-0.00-0.000.530.00-1.88
Issuance of Long Term Debt-0.000.000.000.000.000.580.000.00
Reduction of Long Term Debt--0.00-0.00-0.00-0.00-0.00-0.050.00-1.88
Net Financing Active Other Cash Flow-0.000.000.000.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.000.000.000.00
Cash from Financing Activities-5.224.453.520.104.1414.690.0627.60
Exchange Rate Effect-0.01-0.01-0.01-0.08-0.030.01-0.07-0.06
Net Change in Cash-0.49-0.79-2.00-7.26-4.097.29-18.2323.95
Free Cash Flow--4.77-4.91-5.34-7.36-7.67-12.27-13.07-3.35

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q22025Q1
Cash & Short Term Investments0.410.350.230.941.130.45
Short Term Receivables0.070.060.040.010.040.09
Inventories0.670.670.660.650.681.37
Other Current Assets0.160.190.220.190.150.25
Total Current Assets1.311.261.151.792.002.15
Net Property, Plant & Equipment2.032.072.112.152.193.11
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets5.745.515.275.104.882.00
Other Assets0.000.000.000.000.000.00
Total Assets9.739.509.199.719.747.94
Short Term Debt Incl. Current Port. of LT Debt0.740.930.730.010.010.07
Accounts Payable1.661.621.251.010.630.93
Other Current Liabilities0.700.660.881.130.870.73
Total Current Liabilities3.103.212.872.161.511.73
Long Term Debt0.130.150.190.130.140.14
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.233.363.062.291.651.86
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6.506.136.127.428.096.08
Total Shareholders Equity6.506.136.127.428.096.08
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity6.506.136.127.428.096.08
Total Liabilities & Stockholders Equity9.739.509.199.719.747.94
Book Value Per Share0.060.060.060.080.090.07
Tangible Book Value Per Share0.010.010.010.020.030.05
Full-Time Employees---70--
Price to Book Ratio3.454.544.243.205.773.91
Return on Assets-83.30-90.43-73.03---
Return on Equity-111.15-129.16-105.18---
Return on Invested Capital-30.86-46.74-38.05-9.61-22.13-25.72
Quick Ratio0.210.190.170.530.870.46
Current Ratio0.420.390.400.831.321.25

Cash flow, quarterly

No statement data.

Revenue breakdown

Tolling White Labeling Service2024: 1.16M
Wellness And Lifestyle2024: 113.00K
Colombia2024: 2.00K
United States2024: 1.27M
Colombia2024: 2.00K
United States2024: 1.27M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.46%0.4M86.1M745.41K
2026-10-150.74%0.6M86.1M716.07K
2026-09-301.22%0.9M76.6M672.75K
2026-09-151.41%1.1M76.3M664.17K
2026-08-310.95%0.7M76.3M688.21K
2026-08-141.02%0.8M75.4M636.62K
2026-07-310.74%0.5M73.0M549.79K
2026-07-150.53%0.4M73.0M1.26M
2026-06-300.66%0.5M73.0M1.25M
2026-06-150.27%0.2M77.3M1.19M
2026-05-291.53%1.2M77.0M1.14M
2026-05-151.68%1.3M77.0M1.06M
2026-04-301.53%1.2M76.0M1.06M
2026-04-151.15%0.9M76.0M375.52K
2026-03-310.97%0.7M76.5M368.40K
2026-03-130.88%0.7M76.5M535.36K
2026-02-270.91%0.7M74.2M583.52K
2026-02-130.79%0.6M74.2M589.24K
2026-01-300.81%0.6M73.6M666.82K
2026-01-150.43%0.3M73.7M759.48K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.050.028.5411,4060.000.479-0.0060.000
call1.000.000.100.0410.71438.000.000.441-0.0070.000
call1.500.000.050.0410.9772.000.000.413-0.0070.000
call2.000.000.850.0012.6500.000.000.417-0.0080.000
call2.500.000.050.0713.1251280.000.411-0.0080.000
call5.000.000.850.1714.8205.000.000.397-0.0100.000
call7.500.000.050.0014.6090.000.000.376-0.0090.000
put0.500.050.800.400.00015.000.00-0.521-0.0060.000
put1.000.601.350.900.00020.000.00-0.559-0.0070.000
put1.501.101.901.400.0007.000.00-0.574-0.0080.000
put2.001.602.401.900.0008.000.00-0.583-0.0080.000
put2.502.052.802.400.0007.000.00-0.589-0.0080.000
put5.004.605.404.900.0003.000.00-0.603-0.0090.000
put7.507.107.907.400.0002.000.00-0.610-0.0090.000

Latest SEC filings

0
FiledFormDescriptionPeriodLink
No filings.

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GEODE CAPITAL MANAGEMENT, LLC1.01%
AdvisorShares Investments LLC0.91%
VANGUARD CAPITAL MANAGEMENT LLC0.81%
BlackRock, Inc.0.70%
CITADEL ADVISORS LLC0.44%
VANGUARD FIDUCIARY TRUST CO0.42%
RENAISSANCE TECHNOLOGIES LLC0.29%
STATE STREET CORP0.20%
NORTHERN TRUST CORP0.17%
DEARBORN PARTNERS LLC0.12%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.81%
AdvisorShares Psychedelics ETF0.68%
Fidelity Extended Market Index Fund0.45%
Fidelity Total Market Index Fund0.10%
Fidelity Series Total Market Index Fund0.09%

OakChart. IGC. Cached 15 minutes.

Some panels did not load: ratings, ea, fc, lf.